ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Vizient Medical Device Tech Watch Highlights Data to Help Reduce Readmission Rates in Heart Failure Patients, Surveys Intraoperative Imaging Modalities

Vizient, Inc. today released its latest Medical Device Tech Watch, highlighting data to help reduce readmission rates in heart failure patients and providing a survey of intraoperative imaging modalities. In addition, this issue features one medical center’s journey to increase efficiencies by eliminating its manual “bill only” process for medical devices and products. The full Medical Device Tech Watch can be accessed here.

“The technologies we examine in Tech Watch focus on improving the patient experience and outcomes, reducing the cost to serve, and enabling operations through technology and data,” said Debbie Schuhardt, senior principal, Vizient. “As the healthcare industry evolves and invests in the future, it’s clear that technology and data insights will continue to provide the foundation for providers to meet the needs of their patients.”

This edition contains five articles including:

Reducing heart failure readmissions to improve patient outcomes—Transitioning certain patient- and follow-up care to remote monitoring and assessment for heart failure (HF) patients can reduce the potential for readmissions and free up valuable clinician time and resources for other higher acuity departments. The Vizient Clinical Data Base provides an analysis of more than 380,000 HF patients’ length of stay and average patient cost of care, highlighting opportunities for improved post-discharge practices and reduced readmission rates.

Intraoperative advanced imaging: clinical, financial and operational considerations for adoption—Advances in imaging modalities make near real-time intraoperative images a reality, allowing surgeons to enhance precision, improve quality and outcomes, and decrease the need for surgical revisions. This article provides a survey of intraoperative MRI, CT and ultrasound technologies, reviewing clinical, operational and financial considerations for each. While there is currently no additional reimbursement for the advanced technology, the article lays out strategic considerations for adoption, including increased procedure adoption and staff recruitment.

Transforming the implant bill-only process—When surgeons order implant products that are not pre-purchased, supply chain teams often have difficulty reconciling billing and accounting. These unresolved issues waste significant time for staff who must research and correct discrepancies. One university medical center sought to resolve implant billing issues using a cloud-based platform to automate case usage import from the EMR to the ERP. The result? The center reduced case-date-to-purchase-order-date-time by 70% and reduced bill-only invoice holds by 50%.

Previous issues of Medical Device Tech Watch can be accessed here.

About Vizient, Inc.

Vizient, Inc., the nation’s largest health care performance improvement company, serves more than 60% of the nation’s acute care providers, which includes 97% of the nation’s academic medical centers, and more than 20% of ambulatory care providers. Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents more than $130 billion in annual purchasing volume. Vizient’s solutions and services improve the delivery of high-value care by aligning cost, quality and market performance. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.